Abstract
Emerging SARS-CoV-2 variants pose a threat to human immunity induced by natural infection and vaccination. We assessed the recognition of three variants of concern (B.1.1.7, B.1.351 and P.1) in cohorts of COVID-19 patients ranging in disease severity (n = 69) and recipients of the Pfizer/BioNTech vaccine (n = 50). Spike binding and neutralization against all three VOC was substantially reduced in the majority of samples, with the largest 4-7-fold reduction in neutralization being observed against B.1.351. While hospitalized COVID-19 patients and vaccinees maintained sufficient neutralizing titers against all three VOC, 39% of non-hospitalized patients did not neutralize B.1.351. Moreover, monoclonal neutralizing antibodies (NAbs) show sharp reductions in their binding kinetics and neutralizing potential to B.1.351 and P.1, but not to B.1.1.7. These data have implications for the degree to which pre-existing immunity can protect against subsequent infection with VOC and informs policy makers of susceptibility to globally circulating SARS-CoV-2 VOC.
Competing Interest Statement
Amsterdam UMC filed a patent application on SARS-CoV-2 monoclonal antibodies including the ones used in this manuscript.
Funding Statement
Netherlands Organization for Scientific Research (NWO) Vici grant (RWS) Bill & Melinda Gates Foundation, Collaboration for AIDS Vaccine Discovery (CAVD) grant INV-002022 (RWS) Amsterdam UMC AMC Fellowship (MJvG) Bill & Melinda Gates Foundation, COVID-19 Wave 2 mAbs grant INV-024617 (MJvG) Fondation Dormeur, Vaduz (MJvG, RWS) HIVRAD grant P01 AI 110657 (JPM) R01 AI 36082 (JPM) Netherlands Organization for Health Research and Development ZonMw & the Amsterdam UMC Corona Research Fund (Amsterdam UMC COVID-19 S3/HCW study group)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The COSCA study (NL73281.018.20) included SARS-CoV-2 infected adults and is conducted at the Amsterdam University Medical Center, location AMC and approved by the AMC Medical Ethical Committee (METc). As a control group, sera of 50 fully vaccinated previously uninfected health care workers who were included in the S3 study, which is conducted at both location AMC and VUMc of the Amsterdam University Medical Center (NL73478.029.20) and approved by both AMC and VUMc Medical Ethical Committees (METc).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are available in the main text or the supplementary materials. Reagents used in this study are available upon reasonable request under an MTA with Amsterdam UMC.
